Use of Evidence-Based Therapy for Cardiovascular Risk Factors in Canadian Outpatients With Atrial Fibrillation
| Autor: | Krishnan Ramanathan, Peter Lin, Bruce H. Wheeler, Vidal Essebag, Allan C. Skanes, Lianne Goldin, Brett Heilbron, David J. Gladstone, Charles R. Kerr, Alexandra Silberberg, Mario Talajic, Anatoly Langer, Alan Bell, Jean Grégoire, Claudia Bucci, Carl Fournier, Jafna L. Cox, Martin S. Green, Andrew M. Demchuk, Murray Berall, Paul Dorian, Andrew T. Yan, Paul Angaran, Peter L. Gross, Shaun G. Goodman, L. Brent Mitchell, Mary K. Tan |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Evidence-based practice business.industry Primary care physician Atrial fibrillation 030204 cardiovascular system & hematology medicine.disease Coronary artery disease 03 medical and health sciences 0302 clinical medicine Heart failure Internal medicine medicine Physical therapy Cardiology Sinus rhythm 030212 general & internal medicine Risk factor Cardiology and Cardiovascular Medicine business Risk assessment |
| Zdroj: | The American Journal of Cardiology. 120:582-587 |
| ISSN: | 0002-9149 |
| DOI: | 10.1016/j.amjcard.2017.05.027 |
| Popis: | Using data collected from 2 national atrial fibrillation (AF) primary care physician chart audits (Facilitating Review and Education to Optimize Stroke Prevention in Atrial Fibrillation [FREEDOM AF] and Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation [CONNECT AF]), we evaluated the frequency of, and factors associated with, the use of cardiovascular (CV) evidence-based therapies in Canadian AF outpatients with at least 1 CV risk factor or co-morbidity. Of the 11,264 patients enrolled, 9,495 (84.3%) were eligible for one or more CV evidence-based therapies. The proportions of patients with AF receiving all eligible guideline-recommended therapies were 40.8% of patients with coronary artery disease, 48.9% of patients with diabetes mellitus, 40.2% of patients with heart failure, 96.7% of patients with hypertension, and 55.1% of patients with peripheral arterial disease. Factors that were independently associated with nonreceipt of all indicated evidence-based therapies included sinus rhythm rather than AF at baseline and liver disease. In conclusion, although most Canadian outpatients with AF have CV risk factors or co-morbidities, a substantial portion of these patients did not receive all guideline-recommended therapies. These findings suggest that there is an opportunity to improve the quality of care for patients with AF in Canada. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect